IDKmonitor® Vedolizumab drug level LC-MS/MS

Article number: KMR9600





ESI positive

Pack size

50 Tests

Possible sample matrix and volumes

Serum 50 µl


Regulatory Status

RUO (research use only)

Therapy with biologics is a very effective treatment option for patients suffering from chronic inflammatory diseases. However, there are patients who do not respond to this therapy (primary non-responders) or who develop antibodies against the active substance in the course of treatment (secondary non-responders), i.e. who develop a "resistance" to the specific therapeutic agent.
Therefore, regular monitoring of both the drug level and the formation of antibodies against the drug is important for optimising therapy and the associated long-term therapeutic success. Only through regular monitoring can a secondary therapy failure be recognised at an early stage and possibly prevented.